Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, show...

연구 요약

Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studies.

Frontiers in pharmacology 학술지에 발표된 이 연구는 Feldmüller M, Jodl SJ, Ploeger B 외 연구팀이 수행하였습니다.

이 연구는 'Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studies.'에 대한 과학적 분석을 제공합니다.

핵심 내용

INTRODUCTION: Zabedosertib, the interleukin-1 receptor-associated kinase-4 (IRAK4) inhibitor, is in clinical development as an oral therapeutic for immune-mediated inflammatory diseases and was thoroughly investigated in several phase 1 studies in healthy male volunteers. METHODS: Pharmacokinetics, safety, and tolerability of zabedosertib were characterized in two clinical phase 1 studies with single oral doses up to 480 mg and multiple oral doses up to 200 mg twice daily over 10 consecutive days. The absolute oral bioavailability was determined in a third study using the intravenous microtracer methodology. RESULTS: Zabedosertib showed good safety and tolerability without dose-limiting toxicities or severe infections. An under-proportional increase in exposure was observed with increasing dose. The observed mean accumulation ratios for the area under the concentration-time curve of 1.04-1.62 were lower than expected based on the dose-independent terminal half-life of 19-30 h. The absolute oral bioavailability was 74% at a dose of 120 mg. No food effect was observed. The pharmacokinetics could be described with a one-compartmental population-pharmacokinetic model with first-order elimination, dose-dependent bioavailability, and capacity-limited binding in plasma. The estimation of target occupancy, based on in vitro potency for IL-6 inhibition as a representative pro-inflammatory cytokine in a human whole-blood assay, target residence time, and unbound plasma pharmacokinetics, indicated ∼80% target occupancy over the dosing interval after the maximum feasible dose of 120 mg twice daily. This dose was the highest dose providing relevant exposure increases. CONCLUSION: Based on the projected target occupancy, favorable pharmacokinetics, and safety profile, as well as on distinct pharmacodynamic effects in a proof-of-mechanism study, zabedosertib 120 mg twice daily was selected for further clinical development in patient studies. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/, identifier SAD: NCT03054402, MAD: NCT03493269 (part 1), FE/abs.BA study NCT03244462 (EudraCT numbers: 2016-002668-15, 2017-001817-10, and 2016-004393-18).

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 40520205)

📄 [전문 보기 (Markdown)](fulltext/40520205-zabedosertib-a-novel-interleukin-1-receptor-associated-kinas.md)